TMEM230

TMEM230 is a transmembrane protein of secretory and recycling vesicles, including neuronal synaptic vesicles, that functions in vesicle trafficking, and its disruption is linked to Parkinson's disease through impaired trafficking and alpha-synuclein accumulation (PMID:27270108). Mechanistically, TMEM230 acts upstream of the small GTPase Rab8a to support retromer-dependent cargo sorting (CI-M6PR), autophagic cargo degradation, and Golgi-derived secretion of p62 and lysosomal hydrolases; loss of TMEM230 mislocalizes the retromer, blocks these routes, and causes intracellular cargo accumulation, with rescue by Rab8a establishing the epistatic relationship (PMID:28115417). This Rab8a-centered function converges with LRRK2, whose knockdown phenocopies TMEM230 loss in the same trafficking and secretory-autophagy assays (PMID:28115417). TMEM230 is additionally required for retrograde axonal mitochondrial transport, and both its loss and overexpression of PD-linked variants drive neurodegeneration (PMID:34002226). Across systems, PD-linked variants behave as gain-of-toxic-function alleles: they phenocopy and exacerbate trafficking and transport defects (PMID:28115417, PMID:34002226), while TMEM230 knockout rats show no motor, dopaminergic, autophagy, or Rab-pathway deficits, arguing against simple loss-of-function pathogenesis (PMID:39106917). Beyond neurons, TMEM230 supports growth, adhesion, and pro-angiogenic secretion in glioblastoma cells (PMID:34867197).

1. 2016 High

   Established TMEM230 as a vesicular transmembrane protein and tied it to disease by showing pathogenic mutants impair synaptic vesicle trafficking, defining its core cellular compartment and a candidate disease mechanism.

   Evidence Subcellular fractionation, vesicle localization, and trafficking assays in primary mouse neurons and HEK293 cells with pathogenic variants

   PMID:27270108

   Open questions at the time

   • Molecular partners mediating vesicle trafficking not identified
   • Topology and biochemical activity of the protein not defined
2. 2016 Medium

   Connected impaired TMEM230 trafficking to alpha-synuclein accumulation, providing a plausible link between the vesicular defect and PD pathology.

   Evidence Overexpression of pathogenic variants in HEK293 cells with alpha-synuclein measurement

   PMID:27270108

   Open questions at the time

   • No mechanistic dissection of how trafficking impairment raises alpha-synuclein
   • Single overexpression/western readout
3. 2017 High

   Placed TMEM230 mechanistically upstream of Rab8a, defining its role in retromer cargo sorting, secretory autophagy, and Golgi-derived secretion, and showing PD variants phenocopy loss-of-function.

   Evidence siRNA knockdown, retromer/secretion/autophagy assays, Rab8a rescue, and variant overexpression

   PMID:28115417

   Open questions at the time

   • Direct physical interaction between TMEM230 and Rab8a not shown
   • Mechanism of retromer recruitment unresolved
4. 2017 Medium

   Showed LRRK2 and TMEM230 converge on Rab8a function, embedding TMEM230 in a known PD signaling axis.

   Evidence siRNA knockdown of LRRK2 with comparison of trafficking and secretion phenotypes to TMEM230 knockdown

   PMID:28115417

   Open questions at the time

   • Epistasis is phenotypic, not biochemical
   • Order of action of LRRK2, TMEM230, and Rab8a not resolved
5. 2018 Medium

   Challenged a direct LRRK2-TMEM230 link by failing to detect interaction, phosphorylation, or Rab-level changes, refining how the two proteins relate.

   Evidence Co-IP and kinase assay for LRRK2-TMEM230, western blot for Rab levels after TMEM230 overexpression in dopaminergic cells

   PMID:30460091

   Open questions at the time

   • Negative result; does not exclude indirect functional convergence
   • Single cell line and method
6. 2018 Low

   Identified reduced stability of PD-linked TMEM230 mutant proteins as a possible contributor to their pathogenicity.

   Evidence Protein stability assays comparing WT and R78L/PG5ext mutants in dopaminergic cells

   PMID:30460091

   Open questions at the time

   • Degradation pathway not identified
   • Single lab, single method, no in vivo validation
7. 2021 Medium

   Extended TMEM230 function to retrograde axonal mitochondrial transport and showed both loss and mutant overexpression cause neurodegeneration, broadening its role beyond secretory trafficking.

   Evidence Overexpression and knockdown in SH-SY5Y and mouse primary neurons with live axonal mitochondrial transport imaging

   PMID:34002226

   Open questions at the time

   • Molecular link between TMEM230 and mitochondrial transport machinery unknown
   • Relationship to the Rab8a/retromer role unclear
8. 2021 Medium

   Demonstrated a non-neuronal role for TMEM230 in glioblastoma growth, adhesion, and pro-angiogenic secretion, indicating its trafficking function has broader cellular consequences.

   Evidence siRNA knockdown in U87-MG cells with migration/adhesion assays and conditioned-media HUVEC sprouting assay

   PMID:34867197

   Open questions at the time

   • Secreted pro-angiogenic factors not identified
   • Mechanistic link to the Rab8a secretory pathway not established
9. 2024 Medium

   Argued against simple loss-of-function pathogenesis by showing TMEM230 knockout rats lack PD-relevant motor, dopaminergic, autophagy, and Rab-pathway phenotypes, supporting a gain-of-toxic-function model for mutations.

   Evidence CRISPR-Cas9 knockout rats with motor testing, dopaminergic immunohistochemistry, and western blots for autophagy/Rab/trafficking proteins

   PMID:39106917

   Open questions at the time

   • Possible compensation in knockout not excluded
   • Does not directly test toxicity of mutant alleles in vivo
10. 2025 Medium

    Proposed TMEM230 as a structural subunit of ATP8/ATP11 lipid flippase complexes at endosomes, offering a candidate biochemical activity underlying its trafficking role.

    Evidence Cross-linking mass spectrometry of purified endosomes, AlphaFold modeling, and native gel MS, validated in induced neurons (preprint)

    PMID:bio_10.1101_2025.02.07.636106

    Open questions at the time

    • Preprint, not peer-reviewed
    • Functional contribution of TMEM230 to flippase activity not demonstrated
    • Link to Rab8a/retromer trafficking not established

• The direct biochemical activity of TMEM230 and the molecular mechanism connecting it to Rab8a, the retromer, mitochondrial transport, and putative flippase function remain unresolved.
• No defined enzymatic or binding activity tying together all phenotypes
• Topology and direct partners largely uncharacterized
• How PD mutations exert gain-of-toxic-function not mechanistically defined